Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated informed consent form by the participant or the participant's legally authorized representative~* The participant is ≥ 4 to ≤ 65 years of age~* The participant has a Karnofsky performance score of ≥ 60~* Hemophilia A and B of any severity, with documented history of high-titer inhibitor (\> 5 Bethesda unit (BU)) for at least 12 months; or, if inhibitor titer is ≤ 5 BU, and the participant is refractory with increased dosing of either factor VIII (FVIII) or factor IX (FIX), as demonstrated from the participant's medical history~* Currently being treated on an on-demand basis for treatment of bleeding episodes~* Adequate venous access, with or without central venous device~* ≥ 12 bleeding episodes requiring treatment with by-passing agents in the past 12 months, based on medical history~* Competent in-home treatment and infusion therapy~* Currently using bypassing agents (activated prothrombin complex concentrate (APCC) or recombinant activated factor VII (rFVIIa)) for treatment of bleeding episodes~* HCV-, either by antibody testing or polymerase chain reaction (PCR); or HCV+ with stable hepatic disease~* HIV-, or HIV+ with stable disease and CD4 count \> 200 cells/mm3 at screening~* Female participant of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study~Exclusion Criteria:~* Currently receiving immune tolerance induction (ITI)~* Currently on regular prophylactic therapy to prevent bleeding episodes~* Clinically symptomatic liver disease (e.g. diagnosis of cirrhosis \[confirmed by liver biopsy\], portal vein hypertension, ascites, prothrombin time (PT) 5 seconds above upper limit of normal)~* Platelet count \< 100,000/ml~* Planned elective surgery during participation in this study~* Participant is currently participating in another clinical study and has received an investigational product or device within 30 days prior to study entry~* Planned use of pegylated or non-pegylated alpha-interferon with or without ribavirin for HCV infected participants or planned use of a protease inhibitor for HIV infected participants. Participants currently taking any of these medications for a 30-day course are eligible.~* Clinically significant increase in D-dimer levels from historical baseline and/or associated with chronic liver disease or clinically evident thromboembolic event~* Known hypersensitivity to anti-inhibitor coagulant complexes (AICCs)~* Currently treated with a systemic immunomodulating drug~* Prior history of thromboembolic event: acute myocardial infarction, deep vein thrombosis, or pulmonary embolism~* Diagnosis of advanced atherosclerosis, malignancy and/or other diseases that may increase the participant's risk of thromboembolic complications~* Clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect participant safety or compliance

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prophylaxis arm (Type: EXPERIMENTAL): None
- On-demand arm (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).